VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBIV
Previous Symbol
CUSIPN/A
Phone617-830-3031
Debt
Debt-to-Equity Ratio0.15
Current Ratio1.61
Quick Ratio1.55
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$860,000.00
Price / Sales114.54
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.88 per share
Price / Book0.81
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-38,990,000.00
Net Margins-6,345.29%
Return on Equity-56.88%
Return on Assets-43.93%
Miscellaneous
Employees103
Outstanding Shares64,380,000
Market Cap$90.14 million
OptionableOptionable
VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
How were VBI Vaccines' earnings last quarter?
VBI Vaccines Inc (NASDAQ:VBIV) posted its earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.24 million. VBI Vaccines had a negative return on equity of 56.88% and a negative net margin of 6,345.29%. View VBI Vaccines' Earnings History.
When is VBI Vaccines' next earnings date?
What price target have analysts set for VBIV?
2 brokerages have issued twelve-month target prices for VBI Vaccines' stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate VBI Vaccines' stock price to reach $12.00 in the next year. This suggests a possible upside of 684.3% from the stock's current price. View Analyst Price Targets for VBI Vaccines.
What is the consensus analysts' recommendation for VBI Vaccines?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.
Has VBI Vaccines been receiving favorable news coverage?
News headlines about VBIV stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. VBI Vaccines earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future.
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX), American Brivision (Holding) (ABVC), Evolus (EOLS), Evelo Biosciences (EVLO), OptiNose (OPTN), Stemline Therapeutics (STML), Concert Pharmaceuticals (CNCE), Aclaris Therapeutics (ACRS), Marker Therapeutics (MRKR), Verastem (VSTM), Minerva Neurosciences (NERV), Aratana Therapeutics (PETX), Albireo Pharma (ALBO) and Avid Bioservices (CDMO).
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
- Dr. David Evander Anderson, Chief Scientific Officer (Age 48)
- Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 63)
- Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 41)
- Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 53)
Who are VBI Vaccines' major shareholders?
VBI Vaccines' stock is owned by a number of of institutional and retail investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (2.12%) and Renaissance Technologies LLC (0.10%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc and Steven Gillis. View Institutional Ownership Trends for VBI Vaccines.
Which institutional investors are buying VBI Vaccines stock?
VBIV stock was bought by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc. and Renaissance Technologies LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc and Steven Gillis. View Insider Buying and Selling for VBI Vaccines.
How do I buy shares of VBI Vaccines?
Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBIV stock can currently be purchased for approximately $1.53.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of $90.14 million and generates $860,000.00 in revenue each year. VBI Vaccines employs 103 workers across the globe.
What is VBI Vaccines' official website?
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]
MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
